Results 61 to 70 of about 2,479 (207)
The Journal of Headache and Pain, 2021 Background Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, including the fully humanized monoclonal antibody (IgG2Δa) fremanezumab, have demonstrated safety and efficacy for migraine prevention. Clinical trials include
Stephen D. Silberstein +6 more
doaj +1 more source
Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway [PDF]
, 2023 BACKGROUND: New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine specific medications (nAMSMs ...
Bensink, Mark E +9 more
core +2 more sources
Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase® [PDF]
, 2023 Background: Safety data on the use of migraine preventive monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) system in pregnancy are limited.
Bedussi, Francesca +4 more
core +1 more source
Advanced Science, EarlyView.Paraventricular CRF neurons in the hypothalamus project to glutamatergic neurons of the spinal trigeminal caudal nucleus, enhancing neuronal activation and CRFR2 signaling. This pathway increases CRF release and excitatory drive, promoting central sensitization and migraine‐related behaviors. Targeting the PVN–SP5C circuit provides a potential strategy
Jiang Bian +13 more
wiley +1 more source
Correction to: Fremanezumab: First Global Approval [PDF]
Drugs, 2019 The original article can be found online.
openaire +2 more sources
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
The Journal of Headache and Pain, 2018 Background Fremanezumab (TEV-48125) is a fully humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) that has shown positive results in the prevention of episodic migraine and chronic migraine.
Lena Ohlsson +3 more
doaj +1 more source
Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
Frontiers in Neurology, 2023 BackgroundMedication-overuse headache is highly prevalent in tertiary care centers. It may be a cause or consequence of the overuse of symptomatic medications for migraine attacks.ObjectiveWe aimed to compare the efficacy of anti-CGRP monoclonal ...
Abouch V. Krymchantowski +3 more
doaj +1 more source
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley +1 more source
Frontiers in Neurology, 2022 IntroductionMonoclonal antibodies (mAbs) showed efficacy in migraine prevention. The aim of this study was to check if baseline clinical parameters and cerebral blood flow (CBF) measured by transcranial Doppler (TCD) may help predict mAbs efficacy ...
Magdalena Nowaczewska +6 more
doaj +1 more source